I'd like to call the meeting to order pursuant to Standing Order 108(2), the study on prescription drugs, the common drug review. This is actually our fifth meeting on the common drug review.
I'd like to welcome our witnesses today. We have a range of them. We have, first of all, from the Fraser Institute, Brett Skinner. We'll allow you to start with your presentation. We'll start with yours first, but I'll just introduce who else we have here.
We have the Canadian Diabetes Association and the Canadian Organization for Rare Disorders. We'll introduce those individuals as we yield the floor to them.
With that, we'll ask Mr. Skinner if he would start with his presentation. We're looking forward to it.